Sacral Neuromodulation
Sacral neuromodulation (SNM) is an implantable, reversible therapy that delivers low-amplitude electrical stimulation to the S3 sacral nerve root through a tined lead connected to a subcutaneous pulse generator.[1][2][3] It is used for refractory urgency urinary incontinence (UUI), urgency-frequency syndrome, non-obstructive urinary retention, and fecal incontinence, with a test-stimulation phase before permanent implantation.[1][3][4]
SNM belongs in the same treatment family as Percutaneous Tibial Nerve Stimulation, but it is a different operation: SNM is an implanted sacral-root system; PTNS is tibial-nerve stimulation, usually office-based and non-implantable.
See also: OAB & Urgency Urinary Incontinence, Underactive Bladder, and Fecal Incontinence.
Indications
| Indication | Regulatory / guideline role | Practical selection point |
|---|---|---|
| Urgency urinary incontinence | FDA-approved urinary indication; AUA/SUFU lists SNM among minimally invasive OAB therapies[1] | Refractory UUI or preference for implantable neuromodulation over repeat injections |
| Urgency-frequency syndrome | FDA-approved urinary indication[2][3] | Severe frequency / urgency without another explanatory pathology |
| Non-obstructive urinary retention | FDA-approved urinary indication[2][3] | Idiopathic retention, Fowler-type phenotype, or selected detrusor-underactivity patients after obstruction is excluded |
| Fecal incontinence | FDA-approved in 2011; ASCRS supports SNM as a first-line surgical option with or without sphincter defect[4] | FI episodes despite conservative therapy; successful test phase is the best predictor |
Off-label or emerging uses include IC/BPS frequency-urgency symptoms, selected neurogenic LUTD, chronic pelvic pain, low anterior resection syndrome, and selected pelvic-floor sexual dysfunction phenotypes.[5][6][7][8][9] For IC/BPS, counseling should be especially careful: voiding symptoms may improve, but pain response is less predictable than urgency or frequency response.[5][6]
Mechanism of Action
SNM does not simply "stimulate the bladder." Its effect is multifocal, with peripheral, spinal, and supraspinal modulation.[10][11]
| Level | Proposed effect |
|---|---|
| Peripheral | Activates somatic afferent fibers in the S3 root at low thresholds; pelvic-floor afferent input modulates bladder and bowel reflexes |
| Spinal | Rebalances storage and voiding reflex arcs through interneuronal modulation of sacral parasympathetic output |
| Supraspinal | Alters urgency and control networks involving anterior cingulate cortex, prefrontal cortex, insula, limbic circuitry, and periaqueductal gray |
| Neural plasticity | May produce longer-term changes in sensory processing and reflex gain, though the exact physiology remains incompletely defined |
The clinical effect generally depends on active stimulation. Symptoms may recur when therapy is turned off, although some patients appear to develop longer-lasting neuromodulatory effects.[10][11]
Devices
Current systems include non-rechargeable and rechargeable pulse generators. Modern Medtronic InterStim systems with SureScan leads and Axonics systems support conditional full-body MRI at 1.5T and 3T when device-specific conditions are met.[12][13][14]
| Device family | Battery strategy | Practical tradeoff |
|---|---|---|
| InterStim II / InterStim X | Non-rechargeable | No charging burden; eventual generator replacement |
| InterStim Micro | Rechargeable | Smaller generator and longer expected battery life; requires regular charging[15] |
| Axonics r-SNM systems | Rechargeable and newer non-rechargeable options | Long-life systems with modern MRI labeling; rechargeable systems require patient charging competence[16][17] |
Device choice is not just a technology preference. Frailty, cognition, manual dexterity, access to follow-up, expected MRI needs, and willingness to recharge should all be part of the implant conversation.
Preoperative Evaluation
Before SNM, define the phenotype and exclude problems SNM will not fix:
- Voiding diary, usually at least 3 days
- Urinalysis and treatment of infection if present
- Postvoid residual
- Pelvic exam / focused neurologic exam when relevant
- Urodynamics for complex storage-emptying phenotypes, elevated PVR, prior surgery, suspected obstruction, or neurogenic disease
- Cystoscopy or imaging when hematuria, pain, obstruction, recurrent UTI, or prior reconstruction changes the differential
Relative contraindications include untreated anatomic obstruction, inability to operate the device, inability to recharge a rechargeable system, active infection, pregnancy or planned pregnancy, uncorrected coagulopathy, and need for diathermy.[3][18]
Test Phase
Permanent implantation is usually offered only after the patient demonstrates at least 50% improvement in the key diary variable during test stimulation.[1][3][18]
| Test approach | How it works | Advantages | Limitations |
|---|---|---|---|
| Percutaneous nerve evaluation (PNE) | Office temporary monopolar wire near S3, connected to an external stimulator for 3-7 days | Simple, inexpensive, local anesthesia | Lead migration, short test window, lower conversion rate |
| Staged tined-lead trial | OR placement of permanent quadripolar tined lead connected to an external generator for 2-4 weeks | More reliable lead position, longer test, higher conversion rate | Requires procedure-room / OR resources and later stage-2 implant |
Success is indication-specific: reduction in UUI episodes, reduced frequency, increased voided volumes, fewer catheterizations or lower catheterized volumes, or reduced FI episodes.
Lead Placement Technique
- Position prone on a radiolucent table with the buttocks taped apart.
- Identify S3 fluoroscopically on AP and lateral views.
- Insert the foramen needle toward the cephalad-medial S3 foramen, typically at about a 60-degree skin angle.
- Confirm S3 response with low-amplitude test stimulation.
- Advance the directional guide and introducer through the foramen.
- Place the quadripolar tined lead with a curved stylet.
- Confirm lead trajectory fluoroscopically.
- Deploy tines, remove stylet, and retest electrode responses.
- Connect to a percutaneous extension for staged testing or directly to the generator for single-stage implantation.
Correct S3 response
| Finding | Interpretation |
|---|---|
| Bellows response | Pelvic-floor / levator contraction with visible perineal inward movement; the most important motor response |
| Great toe plantar flexion | Supports S3 placement |
| Perineal, vaginal, scrotal, or rectal sensation | Appropriate sensory field |
| Lateral foot rotation | Suggests S2 rather than S3 |
| No toe movement with anal-only response | Suggests S4 rather than ideal S3 |
Optimal lead placement produces motor and sensory responses at low thresholds on multiple electrodes.[19][20][21]
Stage 2 Implantation
If the test phase is successful, the pulse generator is implanted in an upper-buttock subcutaneous pocket, usually ipsilateral to the lead. The temporary extension is removed, the lead is connected to the implantable pulse generator, impedances are checked, and the pocket is closed.[18][20]
Most patients need postoperative programming and education rather than a single "set and forget" visit.
Programming
Typical starting parameters use low-frequency chronic stimulation:
| Parameter | Common starting point | Practical note |
|---|---|---|
| Frequency | 14 Hz | Standard starting frequency; 31 Hz can be tried as rescue programming |
| Pulse width | 210 microseconds | Shortening pulse width can reduce painful stimulation; pulse-width changes may salvage suboptimal response |
| Amplitude | Sensory or subsensory | Subsensory stimulation can preserve efficacy and improve battery life[22] |
| Configuration | Monopolar or bipolar | Change cathode/anode pattern first when efficacy fades or stimulation is uncomfortable |
Rescue programming usually proceeds by changing electrode configuration, then amplitude, then frequency or pulse width. Programming changes can salvage a meaningful subset of patients with waning efficacy or uncomfortable stimulation.[23][24][25][26]
Outcomes
Urinary indications
The prospective worldwide study reported durable 5-year urinary outcomes: success rates of about 68% for UUI, 56% for urgency-frequency, and 71% for non-obstructive urinary retention.[3] Long-term single-center series report similar durability but substantial reprogramming and revision needs over time.[27][28][29]
Fecal incontinence
ASCRS summarizes pooled FI data showing about 79% of patients achieve at least 50% improvement at 0-12 months and 84% maintain at least 50% improvement beyond 36 months.[4] SNM can work in patients with or without sphincter defects; the best predictor remains a successful test phase rather than sphincter anatomy alone.[4][30]
SNM vs Intradetrusor OnabotulinumtoxinA
ROSETTA randomized women with refractory UUI to SNM or 200 U onabotulinumtoxinA. Botox produced a slightly greater reduction in UUI episodes at 6 months, but with more UTI and intermittent catheterization; SNM avoided injection-related retention but carried device revision / removal risk.[31]
| Issue | Favors SNM | Favors Botox |
|---|---|---|
| Avoiding CIC / retention | No injection-induced retention in ROSETTA | Higher UTI and catheterization risk |
| Avoiding implanted hardware | No | Yes |
| Need for complete UUI resolution | Some meta-analyses show higher complete-resolution signal | Episode reduction can be slightly greater |
| Maintenance burden | Programming, battery, possible revisions | Repeat cystoscopic injections every months |
The right comparison is not "which is better?" but "which burden does this patient prefer: an implantable programmable device or repeat detrusor injections with UTI/retention risk?"
Complications
| Complication | Pattern | Management |
|---|---|---|
| Loss or change of efficacy | Common over long follow-up | Reprogramming first; lead revision if needed |
| Implant-site pain | Early or delayed | Reprogramming, pocket revision, or explantation if severe |
| Lead migration / suboptimal lead | Often early | Reprogramming or lead revision |
| Infection | Usually early | Antibiotics for superficial infection; explantation for pocket or device infection |
| Undesirable stimulation | Leg, perineal, or painful stimulation | Program change, amplitude / pulse-width change, lead revision |
| Battery depletion | Expected for non-rechargeable systems | Generator replacement |
| MRI restrictions | Device-specific | Verify exact device and lead model before MRI |
Revision rates vary widely by era, device, follow-up duration, and definition. Older long-term series report high cumulative reintervention rates, while modern tined leads, MRI-compatible systems, and rechargeable batteries aim to reduce some historical revision drivers.[27][28][29][32]
Special Considerations
MRI
Current-generation systems can be compatible with 1.5T and 3T full-body MRI under manufacturer conditions, but compatibility depends on the exact generator, lead, lead integrity, and scan conditions.[12][13][33][34]
Pregnancy
SNM is commonly turned off during pregnancy because safety data are limited. Reactivation can be considered postpartum if symptoms recur.[18]
Neurogenic LUTD
SNM is most rational in selected incomplete or suprapontine neurogenic phenotypes with refractory OAB or retention. It is not a default therapy for complete spinal cord injury or spina bifida, where bladder behavior and disease progression are more variable.[7]
Key Takeaways
- SNM is an implanted, testable, reversible therapy for refractory OAB/UUI, urgency-frequency, non-obstructive retention, and fecal incontinence.
- A successful test phase is the most important predictor of durable benefit.
- Lead placement lives or dies on correct S3 responses: bellows, great toe plantar flexion, and appropriate perineal sensation at low thresholds.
- Programming is part of the treatment; loss of efficacy should trigger systematic reprogramming before revision.
- Modern device selection should explicitly address MRI needs, recharge burden, cognition, dexterity, and expected lifetime revision risk.
References
1. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985
2. Van Kerrebroeck PE, Marcelissen TA. "Sacral Neuromodulation for Lower Urinary Tract Dysfunction." World J Urol. 2012;30(4):445-450. doi:10.1007/s00345-011-0780-2
3. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. "Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Outcomes of a Prospective, Worldwide Clinical Study." J Urol. 2007;178(5):2029-2034. doi:10.1016/j.juro.2007.07.032
4. Bordeianou LG, Thorsen AJ, Keller DS, et al. "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence." Dis Colon Rectum. 2023;66(5):647-661. doi:10.1097/DCR.0000000000002776
5. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome." J Urol. 2022;208(1):34-42. doi:10.1097/JU.0000000000002756
6. Wang J, Chen Y, Chen J, Zhang G, Wu P. "Sacral Neuromodulation for Refractory Bladder Pain Syndrome/Interstitial Cystitis: A Global Systematic Review and Meta-Analysis." Sci Rep. 2017;7(1):11031. doi:10.1038/s41598-017-11062-x
7. Liechti MD, van der Lely S, Knüpfer SC, et al. "Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction." NEJM Evidence. 2022;1(11):EVIDoa2200071. doi:10.1056/EVIDoa2200071
8. Tutolo M, Ammirati E, Heesakkers J, et al. "Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-Neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain." Eur Urol. 2018;73(3):406-418. doi:10.1016/j.eururo.2017.11.002
9. Fu J, Li Z, Pu J, et al. "Advancing Women's Health: Innovative Applications of Sacral Neuromodulation in Pelvic Floor Dysfunctions." Arch Gynecol Obstet. 2025. doi:10.1007/s00404-025-08182-5
10. Dequirez PL, De Wachter S, Biardeau X. "Sacral Neuromodulation for Low Urinary Tract Dysfunction: Overview and Mechanisms of Action." Auton Neurosci. 2025;261:103337. doi:10.1016/j.autneu.2025.103337
11. Herbison GP, Arnold EP. "Sacral Neuromodulation With Implanted Devices for Urinary Storage and Voiding Dysfunction in Adults." Cochrane Database Syst Rev. 2009;(2):CD004202. doi:10.1002/14651858.CD004202.pub2
12. Huang X, Jiang GJ. "Magnetic Resonance Imaging Interactions With a Sacral Neuromodulation System." Neurourol Urodyn. 2021;40(8):1862-1868. doi:10.1002/nau.24756
13. Medtronic. "MRI Information - Sacral Neuromodulation Therapies." Accessed 2026. https://www.medtronic.com/en-us/healthcare-professionals/specialties/urology/therapies-procedures/sacral-neuromodulation/mri-information.html
14. Axonics. "Axonics System Overview." Accessed 2026. https://www.axonics.com/hcp/axonics-system/system-overview
15. Goudelocke C, Xavier K, Pecha B, et al. "Evaluation of Clinical Performance and Safety for the Rechargeable InterStim Micro Device in Overactive Bladder Subjects: 6-Month Results From the Global Postmarket ELITE Study." Neurourol Urodyn. 2023;42(4):761-769. doi:10.1002/nau.25171
16. McCrery R, Lane F, Benson K, et al. "Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study." J Urol. 2020;203(1):185-192. doi:10.1097/JU.0000000000000458
17. Blok B, Van Kerrebroeck P, de Wachter S, et al. "A Prospective, Multicenter Study of a Novel, Miniaturized Rechargeable Sacral Neuromodulation System: 12-Month Results From the RELAX-OAB Study." Neurourol Urodyn. 2019;38(2):689-695. doi:10.1002/nau.23892
18. Noblett KL, Buono K. "Sacral Nerve Stimulation as a Therapy for Patients With Refractory Voiding and Bowel Dysfunction." Obstet Gynecol. 2018;132(6):1337-1345. doi:10.1097/AOG.0000000000002968
19. Dodge NA, Linder BJ. "Techniques for Optimizing Lead Placement During Sacral Neuromodulation." Int Urogynecol J. 2020;31(5):1049-1051. doi:10.1007/s00192-019-04208-0
20. Matzel KE, Chartier-Kastler E, Knowles CH, et al. "Sacral Neuromodulation: Standardized Electrode Placement Technique." Neuromodulation. 2017;20(8):816-824. doi:10.1111/ner.12695
21. Luchristt D, Amundsen CL. "Strategies for Difficult Fluoroscopic Landmarking During Sacral Neuromodulation Lead Placement." Urology. 2023;174:218-220. doi:10.1016/j.urology.2022.12.029
22. Duelund-Jakobsen J, Buntzen S, Laurberg S, Lundby L. "Improved Longevity and Efficacy of Sacral Nerve Stimulation by Simple Adjustments at Follow-Up." Colorectal Dis. 2020;22(3):310-318. doi:10.1111/codi.14874
23. Lehur PA, Sørensen M, Dudding TC, et al. "Programming Algorithms for Sacral Neuromodulation." Neuromodulation. 2020;23(8):1121-1129. doi:10.1111/ner.13117
24. Dudding TC, Lehur PA, Sørensen M, et al. "Reprogramming Sacral Neuromodulation for Sub-Optimal Outcomes." Neuromodulation. 2021;24(7):1247-1257. doi:10.1111/ner.13494
25. Rueb J, Fascelli M, Goldman HB, et al. "The Role of Pulse Width Manipulation Compared to Program Changes Alone for Unsatisfactory Sacral Neuromodulation Therapy." Neurourol Urodyn. 2021;40(1):522-528. doi:10.1002/nau.24593
26. Averbeck MA, Gajewski JB, Finazzi-Agrò E, et al. "ICI-RS 2024: Rescue Programming in SNM and PTNS." Neurourol Urodyn. 2025;44(3):676-682. doi:10.1002/nau.25600
27. Al-zahrani AA, Elzayat EA, Gajewski JB. "Long-Term Outcome and Surgical Interventions After Sacral Neuromodulation Implant for Lower Urinary Tract Symptoms." J Urol. 2011;185(3):981-986. doi:10.1016/j.juro.2010.10.054
28. Gandhi S, Gajewski JB, Koziarz A, et al. "Long-Term Outcomes of Sacral Neuromodulation for Lower Urinary Tract Dysfunction: A 23-Year Experience." Neurourol Urodyn. 2021;40(1):461-469. doi:10.1002/nau.24583
29. Peeters K, Sahai A, De Ridder D, Van Der Aa F. "Long-Term Follow-Up of Sacral Neuromodulation for Lower Urinary Tract Dysfunction." BJU Int. 2014;113(5):789-794. doi:10.1111/bju.12571
30. Meurette G, Siproudhis L, Leroi AM, et al. "Sacral Neuromodulation With the InterStim System for Faecal Incontinence." Colorectal Dis. 2021;23(6):1463-1473. doi:10.1111/codi.15507
31. Amundsen CL, Richter HE, Menefee SA, et al. "OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women." JAMA. 2016;316(13):1366-1374. doi:10.1001/jama.2016.14617
32. Nanda R, Chen A, Hernandez N, et al. "Factors Contributing to Sacral Neuromodulation Revision: A Single-Center Study." Int Urogynecol J. 2026;37(3):741-747. doi:10.1007/s00192-025-06376-8
33. Karrer-Warzinek E, Abt D, Kim OC, et al. "Safety of Magnetic Resonance Imaging in Patients Under Sacral Neuromodulation With an InterStim Neuromodulator." Urology. 2021;154:115-119. doi:10.1016/j.urology.2021.03.013
34. Heidler S, Ostermann S, Kuglitsch M, et al. "Multiple Magnetic Resonance Imaging in Patients With Implanted Sacral Nerve Stimulator." Neurourol Urodyn. 2020;39(8):2368-2372. doi:10.1002/nau.24496